Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Saved in:
| Title: | Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. |
|---|---|
| Authors: | Lynce F; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu., Mainor C; MedStar Georgetown University Hospital, Washington, DC, USA., Donahue RN; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Geng X; Georgetown University, Washington, DC, USA., Jones G; NeoGenomics, Durham, NC, USA., Schlam I; MedStar Washington Hospital Center, Washington, DC, USA.; Tufts Medical Center, Boston, MA, USA., Wang H; Georgetown University, Washington, DC, USA., Toney NJ; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jochems C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schlom J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zeck J; MedStar Georgetown University Hospital, Washington, DC, USA., Gallagher C; MedStar Washington Hospital Center, Washington, DC, USA., Nanda R; University of Chicago, Chicago, IL, USA., Graham D; Hackensack University Medical Center, Hackensack, NJ, USA., Stringer-Reasor EM; University of Alabama at Birmingham, Birmingham, AL, USA., Denduluri N; AstraZeneca, Arlington, VA, USA., Collins J; MedStar Georgetown University Hospital, Washington, DC, USA.; AstraZeneca, Arlington, VA, USA., Chitalia A; MedStar Washington Hospital Center, Washington, DC, USA., Tiwari S; MedStar Washington Hospital Center, Washington, DC, USA., Nunes R; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; AstraZeneca, Arlington, VA, USA., Kaltman R; Inova, Fairfax, VA, USA., Khoury K; University of Alabama at Birmingham, Birmingham, AL, USA., Gatti-Mays M; The Ohio State University, Columbus, OH, USA., Tarantino P; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Swain SM; Georgetown University, Washington, DC, USA., Pohlmann P; MedStar Georgetown University Hospital, Washington, DC, USA., Parsons HA; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isaacs C; Georgetown University, Washington, DC, USA. |
| Source: | Nature communications [Nat Commun] 2024 May 10; Vol. 15 (1), pp. 3957. Date of Electronic Publication: 2024 May 10. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-48359-1 |
